How to buy Seneca Biopharma stock

Seneca Biopharma, Inc is an other business based in the US. Seneca Biopharma shares (CUR) are listed on the NASDAQ and all prices are listed in US Dollars. Seneca Biopharma employs 5 staff and has a market cap (total outstanding shares value) of 0.00.

Seneca Biopharma stock price (NASDAQ: CUR)

Use our graph to track the performance of CUR stocks over time.

Seneca Biopharma shares at a glance

• Key figures

Information last updated 2021-01-22.

52-week range	$0.42 - $0.73
50-day moving average	$0.00
Wall St. target price	$26.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-7.83

Buy Seneca Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Seneca Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Seneca Biopharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Seneca Biopharma financials

Gross profit TTM	$0
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	0%
Book value	$2.50
Market capitalisation	$4 million

TTM: trailing 12 months

Seneca Biopharma share dividends

We're not expecting Seneca Biopharma to pay a dividend over the next 12 months.

Seneca Biopharma overview

Seneca Biopharma, Inc. , a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. The company was formerly known as Neuralstem, Inc.

Frequently asked questions

How many people work for Seneca Biopharma?
Latest data suggests 5 work at Seneca Biopharma. When does the fiscal year end for Seneca Biopharma?
Seneca Biopharma's fiscal year ends in December. Where is Seneca Biopharma based?
Seneca Biopharma's address is: 20271 Goldenrod Lane, Suite 2024 20876,Germantown,USA What is Seneca Biopharma's ISIN number?
Seneca Biopharma's international securities identification number is: US81689B1035 What is Seneca Biopharma's CUSIP number?
Seneca Biopharma's Committee on Uniform Securities Identification Procedures number is: 64127R302